Maybe if I had said 'cash-heavy'? I'm sure there are dozens of poorly capitalized companies who would drool at the thought of magically acquiring the IP of ILNS.
However, is there a well funded, perhaps cash-heavy company in the arena?
And....by 'arena' I mean the small or 'Boutique' bio-med arena.
Why do you think a partner/buyout candidate should or will come from the "small or 'Boutique' bio-med arena" ?
Wouldn't a BP, that is cash-heavy, be more favorable? Some time ago I pointed to Eli Lilly that try to push their Alzheimer development forward and that are interested especially in the field of tau or combined Amyloid/tau therapeutics where ILNS has a lot of patents and patent application to secure the IP.
And there are of course others that could very well use the IP and developments of ILNS.